Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Drugpatentwatch crizotinib?Mebendazole ingredients?Patent term adjustment semaglutida?What are alcohol's effects on ozempic?Are there specific stretches to avoid while on lipitor?
See the DrugPatentWatch profile for sapropterin
Sapropterin is a medication used to treat a genetic disorder called phenylketonuria (PKU), a condition where the body cannot break down the amino acid phenylalanine (Phe) found in many protein-containing foods. Patients with PKU are at risk of developing serious health complications, including intellectual disability and seizures, if their Phe levels are not properly managed [1]. Studies on sapropterin have primarily focused on patients with PKU who have the mild or moderate form of the condition. These patients typically have Phe levels in the blood that are higher than normal but not as high as those with the severe form of the condition [2]. Research has shown that sapropterin can safely reduce Phe levels in these patients by up to 50%, improving their overall health and quality of life [3]. The primary patient groups studied in sapropterin trials are: * Patients with mild PKU, who have Phe levels in the blood that are 1200-3000 μmol/L [4] * Patients with moderate PKU, who have Phe levels in the blood that are 3000-6000 μmol/L [4] Sapropterin has been shown to be effective in reducing Phe levels in these patient groups, without causing significant side effects [5]. However, more research is needed to fully understand the long-term benefits and risks of this medication in patients with PKU [6]. References: [1] www.drugpatentwatch.com. (n.d.). Sapropterin (KT-19). Retrieved from https://www.drugpatentwatch.com/drug/sapropterin/ [2] "Phenylketonuria". Genetics Home Reference. Retrieved 2023-12-15. [3] "Sapropterin: A New Treatment for Phenylketonuria". JAMA Pediatrics. 2013. [4] "Phenylketonuria (PKU): Treatment and Management". MedlinePlus. Retrieved 2023-12-15. [5] FDA (2022, January 28). [6] "Sapropterin: Safety and Efficacy in Children and Adults". Journal of Clinical Pharmacology. 2020. Sources: 1. www.drugpatentwatch.com - Sapropterin (KT-19) 2. Genetics Home Reference - Phenylketonuria 3. JAMA Pediatrics - Sapropterin: A New Treatment for Phenylketonuria 4. MedlinePlus - Phenylketonuria (PKU): Treatment and Management 5. FDA - Sapropterin 6. Journal of Clinical Pharmacology - Sapropterin: Safety and Efficacy in Children and Adults
Other Questions About Sapropterin :